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Abstract 
 
Loss of adenomatous polyposis coli (APC) function is typically an early event in sporadic colorectal cancer (CRC) 
pathogenesis. The key tumor suppressor function of the APC protein lies in its ability to destabilize free cytoplasmic 
beta catenin. This lead to the accumulation of nuclear beta catenin, and together with the DNA binding protein Tcf-4, 
function as a transcriptional activator. Accumulation of stabilized free β-catenin is considered as an early event and 
perhaps initiating the process in intestinal tumorigenesis. Neoplastic transformation in the CRC associated chronic 
colitis is considered similar to the adenoma-carcinoma sequence in sporadic CRC. The distinguish feature from the 
CRC-related colitis is the difference in time and frequency changes. Loss of APC function, regarded as the beginning of 
a very common event in sporadic CRC, but the CRC associated chronic colitis generally occurs at the end of the 
dysplasia-carcinoma sequence. This research was conducted to determine the subcellular location of beta catenin 
expression in chronic colitis, colorectal adenomas and carcinomas that were evaluated by immunohistochemical 
staining. It can be concluded that beta-catenin is a component that plays a role in the development of the CRC and the 
subcellular location of beta-catenin can describe its oncogenic activity. 
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Introduction 
 
Colorectal cancer (CRC) is a significant cause of 
morbidity and mortality in the developed world with 
over 142.570 new cases diagnosed annually around the 
world.1 Although patients diagnosed with early stage 
disease have a high cure rate, many present later when 
five year survival is poor.2 Increased understanding of 
the changes in specific molecular pathways that are 
responsible for disease progression and poor prognosis 
may prove essential in the development of more 
effective targeted treatment. 
 
It has been suggested that colorectal cancer (CRC) 
progression arises from an accumulation of several 
genetic changes from normal mucosa to adenoma and 
then carcinoma. This pathway requires the accumulation 
of genetic alteration which preceded by the inactivation 
of tumor suppressor gene adenomatous polyposis coli 
(APC). Mutation of APC was found in up to 80% of 
sporadic CRC and adenoma and was thought to be 
critical in the development of colorectal cancer.3  
 
Beta catenin is a multifunctional protein that is involved 
in cell–cell interaction and transcriptional signaling. In 
normal colonic epithelial cells, beta catenin is 
predominantly bound to E-cadherin as part of a cell to 
cell adhesion complex on the lateral cell membrane. 
Cytoplasmic beta catenin levels are regulated by 
binding to a protein complex consisting of APC, 
glycogen synthase kinase-3 beta, and axin, followed by 
ubiquitin/proteasome degradation.4  
 
In colorectal cancers, mutations of APC or beta catenin 
result in stabilization of beta catenin and a significant 
accumulation of this protein within the cytoplasm. 
Furthermore, increased beta catenin may translocate to 
the nucleus and could serve as a transcriptional factor 
by binding to the T-cell factor/lymphoid enhancing 
factor (Tcf-Lef) family, leading to transcription of 
specific genes stimulating tumor formation, such as 
cyclin-D1, c-myc, c-jun, and fra-1.5 
 
Chronic inflammation has been known to have an 
important role in the development of various types of 
cancer, including colon cancer carcinogenesis through 
chronic colitis associated CRC.6 Chronic colitis-related 
neoplastic progression may be associated with different 
beta catenin pathway alterations than sporadic 
carcinogenesis because of its origin in a field of chronic 
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inflammation.7 Although the role of the APC gene 
mutations in carcinogenesis is still unclear, but it has 
been reported frequency of APC gene mutations in 
ulcerative colitis-related neoplasia varies from 0-50%.8 
Other studies show the APC protein expression in 80% 
of cases of ulcerative colitis-related carcinoma. This 
indicates that the path APC beta catenin may play a 
more important role in relation to carcinogenesis 
chronic colitis than those found before.7-8 In this study, 
we investigated the expression pattern of beta catenin in 
colorectal non neoplastic and neoplastic lesion by 
immunohistochemical staining. 
 
Methods 
 
Samples. The study population consisted of four groups 
of each 30 patients retrieved by a retrospective search 
through the pathology files of the Department of 
Anatomical Pathology, University of Indonesia in 2009. 
The first group consisted of patient with clinically, 
endoscopically and pathologically confirmed CRC. All 
specimen from this group of patients consisted of 
colonic resection samples. Invasive adenocarcinoma 
was diagnosed when atypical cells or glands infiltrated 
into the submucosa.9 The adenocarcinomas were graded 
as well-differentiated (grade 1), moderately differentiated 
(grade 2), or poorly differentiated (grade 3), and the 
depth of invasion was determined.9,10 The second group 
consisted of adenoma. An adenoma was defined as a 
discrete, well defined, sessile or pedunculated polyp and 
histological architecture (tubular, tubulovillous, villous), 
and the dysplasia was graded as low- or high-grade.9 
The patient had no history of pancolitis. All specimens 
consisted of polypectomy samples. The third group 
consisted of patient with chronic colitis. Endoscopically 
biopsy samples of chronic colitis were confirmed when 
there was expansion of the lamina propria by plasma 
cells or eosinophils or accompanying glandular 
distortion.11 The fourth group consisted of normal 
colorectal mucosa of the resection margin. 
 
Beta catenin immunostaining. Briefly, sections were 
deparaffinized and rehydrated through graded alcohol. 
Endogenous peroxidase activity was blocked with 0.5% 
hydrogen peroxide in methanol for 20 minutes. Antigen 
retrieval was used by microwave treatment; dilution was 
1:100 for beta catenin (Novocastra, United Kingdom). 
Biotinylated universal antiserum (Starr Trek HRP 
Universal, Biocare Medical, CA) was used as the 
secondary antibody. After washing, the slides were 
incubated for 20 minutes at room temperature with 
Trekavidin HRP label (Starr Trek HRP Universal 
Biomedical CA) and developed for 10 minutes using 3-
3’diaminobenzidine as chromogen. After rinsing in 
water, the sections were counterstained with Meyer 
haematoxylin, dehydrated, and mounted. Appropriate 
positive and negative controls were included in each run 
of immunohistochemistry. 
Beta catenin evaluation.12,13 Normal colonic epithelial 
cells served as internal positive controls with membrane 
staining (Figure 1). Cytoplasmic, nuclear, and 
membrane expressions were recorded separately. The 
percentage of cells with membranous, cytoplasmic and 
nuclear positivity was graded as follows: 0) <5%, 1) 5–
25%, 2) 26–50%, 3) 51–75%, 4) >75%. The staining 
intensity was graded as (0) negative, no expression, or 
(1) positive, positive expression. Cytoplasmic staining 
was graded to 3 categories: (0) negative, no detectable 
staining, (1) weak, but still detectable staining, (2) 
heavy staining, intense. The nuclear staining was also 
graded to into 3 categories: (0) negative, only blue 
staining seen, (1) weak, blue staining clearly seen 
through brown staining, and (2) heavy staining, blue 
scarcely seen through brown staining, nuclei appear 
darker than the cytoplasm, or no blue seen through 
brown staining. Immunohistochemistry scores obtained 
by multiplying the “percentage of positive cells” by the 
“staining intensity” and expressed as negative (score 0), 
weak (score 1–4), strong (score 5–8). 
 
All immunohistochemically stained slides were 
evaluated using regular light microscopy by one of the 
investigators blinded from any other clinical and 
laboratory data. A second observer examined 30 cases 
randomly, and kappa coefficients for agreement in these 
30 cases were as follows: 0.525 for cytoplasmic 
positivity, 0.753 for nuclear positivity, 0.737 for 
membrane positivity, indicating overall moderate to 
substantial agreement. 
 
Kruskal-Wallis test was used to evaluate the 
relationship between the expression of beta catenin and 
progression and expression of beta catenin and 
differentiation. Mann-Whitney test was used to evaluate 
the relationship between the expression of beta catenin 
and degree of dysplasia. SPSS for Windows 13.0 
(SPSS, Chicago, IL) software was used to analyze the 
data. For statistical significance, the cut off point for p-
value was set at 0.05.  
 
Results and Discussion 
 
A summary of the clinicopathologic features of the 
specimens are illustrated in Table 1. Beta catenin 
immunostaining in normal colonic mucosa is performed 
and give similar results with previous studies.12-14 All 
normal colorectal mucosal showed membranous 
expression of beta-catenin and was used as an internal 
positive control (Figure 1). 
 
This study showed a significant increase for beta-
catenin expression during the progression from normal 
epithelium to carcinoma (p = 0.000). Membranous and 
cytoplasmic expression of beta-catenin was increased 
with progression of carcinogenesis (Table 2, Figure 2). 
Hao et al.  found  an  association  between  
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cytoplasmic expression of beta-catenin in 54% cases of 
dysplastic aberrant crypt foci and concluded that this 
process is the earliest changes in colorectal 
carcinogenesis.12 Similar results also come from 
Elzagheid et al. who discovered nearly 100% 
membranous and cytoplasmic expression of beta-
catenin in CRC and adenoma.14 
 
Table 1. Clinicopathologic Characteristic 
 
Normal Colitis Adenoma  Carcinoma  Parameter 
n (%) n (%) n (%) n (%) 
Sex     
 Male 15 (53) 13 (21) 12 (40) 16 (53) 
 Female 14 (47) 17 (29) 18 (60) 14 (47) 
Age (year)     
 <40  5 (17) 12 (40) 4 (13) 5 (17) 
 41 – 50 5 (17) 3 (10) 5 (17) 5 (17) 
 51 – 60 12 (40) 9 (30) 12 (40) 12 (40) 
 >60 8 (26) 6 (20) 9 (30) 8 (26) 
Tumor location    
 Right sided 4 (13) 2 (6) 7 (23) 
 Left sided 11 (37) 8 (26) 14 (46) 
 Rectum 15 (50) 20 (66) 9 (30) 
Histopathologic type   
 Adenocarcinoma  29 (96) 
 Mucinous carcinoma  1 (3) 
 Tubular adenoma 4 (13)  
 Tubulovilous adenoma 6 (20)  
 Vilous adenoma 3 (10)  
Tumor differentiation   
 Well  13 (43) 
 Moderate  9 (30) 
 Poor  7 (23) 
Dysplasia degree   
 Low grade 6 (20)  
 High grade 24 (80)  
Tumor staging   
 T1  0 (0) 
 T2  8 (26) 
 T3  22 (73) 
 T4  0 (0) 
Lymph node status   
 Nx  11 (37) 
 N0  4 (13) 
 N1  12 (40) 
 N2  3 (10) 
 
 
 
 
Figure 1. Membranous Expression of Beta Catenin in Colorectal Normal Mucosa 
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Beta catenin is a multifunctional protein complex which 
is a component of cell-to-cell adhesion and part of the 
WNT signaling pathway to be degraded by the 
degradation complex APC-Axin-GSK-3B. In cells with 
two mutant APC alleles, beta-catenin degradation does 
not occur and cause increased accumulation of beta-
catenin in the cytoplasmic.15 
 
Accumulation of beta-catenin in the nucleus was 
detected in almost all (96%) CRCs (Figure 3). This 
proves that beta-catenin is a key factor in colorectal 
carcinogenesis. Cheah et al. and Baldus et al. reported 
the nuclear expression of beta catenin in sporadic CRC 
between 21-100% and support our results (Table 2). 
Some explanation of the variation results including the 
heterogeneity of the tumor, different immunostaining 
procedure, lack of standardization evaluation of positive 
and negative results as well as different methods of 
determining the degree of differentiation.16,17 
 
This study did not find the relationship between beta-
catenin expression (membrane, cytoplasm and nucleus) 
with the degree of dysplasia (p> 0.05) (Table 3). This is 
similar with the result from Elzagheid et al. and Hao et 
al.12,14 Beta-catenin expression is increased in the 
membrane and cytoplasm can be detected at an early 
stage, while the nucleus translocation occurs at an 
advanced stage to carcinoma and this illustrates the 
stages of genetic mutations in normal epithelium 
developed into CRC.12 
 
Wanitsuwan et al. discovered a correlation between 
beta-catenin expression with the degree of 
differentiation. This suggests that beta catenin may 
function to maintain the status of cell differentiation in 
carcinoma.18 Although this study did not find the 
relationship between expression of beta-catenin with 
tumor differentiation (Table 3), but in carcinomas with 
mucinous component and poorly differentiated tumors 
generally showed lower frequency of beta-catenin 
expression and a higher membrane expression compared 
with carcinoma without mucinous components and 
moderate or good differentiation. 
 
To the best of our knowledge, there were no studies that 
investigated the expression of beta-catenin in non-
neoplastic lesions of the colon, such as chronic colitis. 
We used a chronic colitis with glandular distortion as 
Table 2. Beta Catenin Expression in Normal Mucosa, Chronic Colitis, Colorectal Adenoma and Carcinoma 
 
    Normal Colitis Adenoma Carcinoma p value 
Membrane percentage 
 <5 0 (0) 0 (0) 3 (10) 0 (0) 
 6-25 0 (0) 0 (0) 6 (20) 3 (10) 
 26-50 1 (3) 0 (0) 3 (10) 3 (10) 
 51-75 0 (0) 1 (3) 7 (23) 11 (36) 
 >75 29 (97) 29 (97) 11 (36) 13 (43) 
Cytoplasmic score 
 Negative 12 (40) 10 (33) 0 (0) 0 (0) 
 Weak 9 (30) 19 (63) 13 (43) 5 (16) 
 Strong 9 (30) 1 (3) 17 (56) 25 (83) 
Nuclear score 
 Negative 30 (100) 29 (97) 8 (26) 1 (3) 
 Weak 0 (0) 1 (3) 10 (33) 12 (40) 
  Strong 0 (0) 0 (0) 12 (40) 17 (56) 
p = 0.000 
 
 
 
 
 
Figure 2. Membranous and Cytoplasmic Expression of 
Beta Catenin in Colorectal Adenoma 
 Figure 3. Strong Cytoplasmic and Nuclear Expression 
of Beta Catenin in Colorectal Carcinoma 
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Table 3. Beta Catenin Expression in Colorectal Adenoma and Carcinoma 
 
    Dysplasia degree Tumor differentiation 
        Low     High      Well Moderate Poor 
p value 
Membrane percetage       
 <5 0 (0) 3 (10)  0 (0) 0 (0) 0 (0) 
 6-25 0 (0) 6 (20)  2 (6) 1 (3) 0 (0) 
 26-50 1 (3) 2 (6)  1 (3) 0 (0) 2 (6) 
 51-75 2 (6) 5 (16)  4 (13) 4 (13) 3 (10) 
 >75 3 (10) 8 (27)  6 (20) 4 (13) 3 (10) 
Cytoplasmic score       
 Negative 0 (0) 0 (0)  0 (0) 0 (0) 0 (0) 
 Weak 4 (13) 9 (30)  3 (10) 1 (3) 2 (6) 
 Strong 2 (6) 15 (50)  10 (33) 8 (27) 6 (20) 
Nuclear score       
 Negative 2 (6) 6 (20)  1 (3) 0 (0) 0 (0) 
 Weak 3 (10) 7 (23)  4 (13) 3 (10) 5 (16) 
  Strong 1 (3) 11 (37)   8 (27) 6 (20) 3 (10) 
p > 0.05 
 
 
 
 
Figure 4. Membranous and Cytoplasmic Expression of 
Beta Catenin in Chronic Colitis. No Nuclear 
Expression of Beta Catenin 
 
 
one of research materials to investigate the beta-catenin 
expression changes due to the chronic inflammatory 
process that can cause carcinogenesis. Inflammation 
through the free radicals can cause damage to DNA, 
fats, and proteins. DNA damage with the increase 
proliferation of can cause persistent gene mutations.6,7 
 
Our research shows extensive expression of the 
membrane in all cases (100%) of chronic colitis (Table 
2, Figure 4). We found cytoplasmic expression of beta 
catenin in 20 cases (66.7%) and weak nuclear 
expression in one case (3.3%). Cooper et al. who 
investigated the dysplastic lesions in chronic colitis 
using mouse model discovered alteration in cytoplasmic 
and/or nuclear expression of beta-catenin in 10 cases 
(100%) of DALM (Dysplasia Associated Lesion/Mass).19 
Sixteen of 17 cases (94.2%) flat dysplasia showed 
membrane expression of beta-catenin and in one of 17 
cases (5.8%) gave cytoplasm and nuclear expression. 
These results indicate translocation of beta-catenin is 
involved in polipoid dysplastic lesions rather than flat 
dysplastic lesions and suggest an important role of beta-
catenin in the early molecular events in polypoid 
lesions. This study found no association between the 
location of expression (membrane, cytoplasm, and 
nucleus) beta-catenin with the clinical variables (age, 
gender, and location of the tumor). Some studies find 
similar results except for the tumor location. Kawasaki 
et al. and Elzagheid et al. reported the increased 
cytoplasm and nuclear expression of beta-catenin in 
right sided tumor than the left side and rectum.13,14 The 
involvement of different molecular mechanism in 
colorectal carcinogenesis, in which the adenoma 
carcinoma sequence of carcinogenesis generally occurs 
on the left side of the colon and rectum while the 
mutator phenotype occurs in the right side. 
 
The relationship between the location of beta-catenin 
expression and clinical outcome is still the subject of 
controversy. In a study involving 60 CRC, nuclear beta-
catenin expression predicts a poorer survival.20 Research 
in 650 CRC showed beta-catenin expression was not 
associated with survival rates at.21 Recent research 
involving 60 CRC found no predictive value for the 
nuclear beta catenin expression, but the expression on 
the membrane, cytoplasm and nucleus associated with 
better differentiation and lower stage of disease.22 In a 
study for 95 stage IV CRC membrane beta catenin 
expression associated with higher cure rates.23 Recent 
data show suppression of beta-catenin can inhibit the 
development of mutant APC CRC.24 
 
Conclusion 
 
Subcellular localization of beta-catenin can reflects its 
oncogenic activity thus beta-catenin is a component that 
plays a role in the development of the CRC. Although 
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the role in chronic inflammatory setting can not be 
determined yet, it is acceptable that beta catenin 
involved in the inflammatory process and may play an 
important role. Further studies are needed to see the 
relationship of other factors that played a role in Wnt 
signaling pathway/beta-catenin, like APC protein, beta-
catenin, axin and GSK-3b to get a comprehensive 
understanding of beta-catenin activity that can be used 
for the development of preventive agent in the future. 
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